<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239563</url>
  </required_header>
  <id_info>
    <org_study_id>Oxford/OTC/TIKT</org_study_id>
    <secondary_id>2009-016676-73</secondary_id>
    <nct_id>NCT01239563</nct_id>
  </id_info>
  <brief_title>Thymoglobulin Induction in Kidney Transplant Recipients</brief_title>
  <acronym>TIKT</acronym>
  <official_title>THYMOGLOBULIN INDUCTION AND STEROID-FREE IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION FROM DECEASED DONORS AFTER CARDIAC DEATH-AN OPEN LABEL RANDOMISED CONTROLLED TRIAL TO EVALUATE THE ROLE OF THYMOGLOBULIN AS INDUCTION IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTS FROM DECEASED DONORS AFTER CARDIAC DEATH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline)&#xD;
      administration in the kidney transplant recipient is able to reduce the amount of damage that&#xD;
      kidneys transplanted from deceased donors sustains on reperfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing disparity between organ availability and the number of patients on waiting&#xD;
      list for a transplant has led to different strategies to improve half life of all&#xD;
      transplants. One such method is to reduce the amount of damage the organ sustains during the&#xD;
      period of preservation and reperfusion in the recipient. Thymoglobulin, an anti-lymphocyte&#xD;
      antibody has been shown to have the ability to reduce this damage in experimental studies.&#xD;
      This study aims to ascertain the role of Thymoglobulin in kidney transplants from donors&#xD;
      after cardiac death, the type of kidney transplants at highest risk of sustaining injury&#xD;
      during preservation. The study will involve comparison with conventional immunosuppressant&#xD;
      therapy, comparison between Thymoglobulin administered in different doses, and observation of&#xD;
      the patterns of blood cell repopulation (lymphocytes mainly) in the first year following&#xD;
      kidney transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delayed graft function</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>steroid avoidance</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphocyte repopulation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Ischemia-Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin induction group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basiliximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Basiliximab induction - 20 mg, day 0 and day 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antithymocyte globulin</intervention_name>
    <description>Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose</description>
    <arm_group_label>Thymoglobulin</arm_group_label>
    <other_name>Thymoglobulin, L04AA04</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Intravenous 20mg, day 0&amp;4</description>
    <arm_group_label>Basiliximab</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study&#xD;
&#xD;
          -  Male or Female, aged 18 years or above&#xD;
&#xD;
          -  Recipient of DCD kidney transplant&#xD;
&#xD;
          -  Female participants of child bearing potential and male participants whose partner is&#xD;
             of child bearing potential must be willing to ensure that they or their partner use&#xD;
             effective contraception during the first 12 months of the study&#xD;
&#xD;
          -  Able (in the Investigators opinion) and willing to comply with all study requirements&#xD;
&#xD;
          -  Willing to allow his or her General Practitioner and consultant, if appropriate, to be&#xD;
             notified of participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant may not enter the study if ANY of the following apply:&#xD;
&#xD;
          -  Failure of either recipient of a pair of kidneys to give consent&#xD;
&#xD;
          -  Female participant who is pregnant, lactating or planning pregnancy during the course&#xD;
             of the study.&#xD;
&#xD;
          -  History of specific viral infection that would contraindicate depleting antibody&#xD;
             therapy e.g. hepatitis B&amp;C, HIV&#xD;
&#xD;
          -  Significant hepatic impairment-.i.e. Values 3 times upper limit of normal (unless this&#xD;
             is usual for the subject)&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the study, or may&#xD;
             influence the result of the study, or the participant's ability to participate in the&#xD;
             study&#xD;
&#xD;
          -  Participants who have participated in another research study involving an&#xD;
             investigational product in the previous 12 weeks&#xD;
&#xD;
          -  Previous administration of Thymoglobuline&#xD;
&#xD;
          -  Patients with functioning non-renal transplants and on immunosuppression&#xD;
&#xD;
          -  The patient is not suitable, in the opinion of the Investigator, to take part in the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Friend, MD FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan V Fuggle, DPhil MRCPath</last_name>
    <role>Study Director</role>
    <affiliation>Oxford Radclifffe Hospitals NHS Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Wood, DPhil BSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anand Sivaprakash Rathnasamy Muthusamy, MBBS MRCS</last_name>
    <phone>44 1865 741841</phone>
    <email>anand.muthusamy@orh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens Brockmann, MD</last_name>
    <phone>44 1865 741841</phone>
    <email>jens.brockmann@nds.ox.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oxford Transplant Centre, Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan V Fuggle, DPhil MRCPath</last_name>
      <phone>44 1864 226162</phone>
      <email>susan.fuggle@nds.ox.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oxford</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathryn Wood, DPhil BSc</last_name>
    </contact>
    <investigator>
      <last_name>Peter J Friend, MD FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathryn Wood, DPhil BSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Peter Friend / Professor of Transplantation</name_title>
    <organization>University of Oxford</organization>
  </responsible_party>
  <keyword>kidney transplantation</keyword>
  <keyword>donation after cardiac death</keyword>
  <keyword>ischemia-reperfusion injury</keyword>
  <keyword>thymoglobulin</keyword>
  <keyword>steroid avoidance</keyword>
  <keyword>lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

